According to the latest disclosure documents from the U.S. Securities and Exchange Commission, biotechnology company Solid Biosciences has submitted a resale prospectus, and a certain shareholder of the company plans to resell up to 1.3 million shares of common stock.

This filing provides a legal basis for subsequent market transactions, with the resale scale accounting for a certain proportion of the company’s circulating shares. The document shows that the transaction will be conducted through public market channels, and the specific sale time and price will be determined according to market conditions. As a biopharmaceutical company focused on gene therapy research and development, Solid Biosciences has recently experienced significant stock price fluctuations. This shareholder reduction plan may have some impact on the liquidity of the secondary market, and investors should pay attention to subsequent changes in shareholding.